Literature DB >> 32408771

Acceptability and preferences for long-acting antiretroviral formulations among people with HIV infection.

Dima Dandachi1,2, Bich N Dang2,3,4,5, Brandon Lucari5, Susan Swindells6, Thomas P Giordano2,3,4,5.   

Abstract

The study evaluates the acceptability and preferences for long-acting antiretroviral therapy (LA-ART) among a diverse cohort of people with HIV infection (PWH). It consists of a self-administered survey and chart review of PWH presenting to an HIV clinic in Houston, Texas, between February and June 2018; 374 participants were included; 61% indicated that they were likely or very likely to use LA-ART formulations. When asked about preference, 41% preferred pills, 40% preferred injections, and 18% preferred an implant. The most common benefit reported was eliminating the need to remember taking daily HIV pills (74%); 43% were worried that LA-ART will not be as effective as pills. Participants with a college degree, men who have sex with men, and ART-experienced were more willing to use LA-ART. Participants who reported poor or fair health, or who screened positive for depression or anxiety were significantly less willing to use LA-ART. The likelihood of using LA-ART did not correlate with self-reported adherence and HIV suppression. Patients with difficulty scheduling and attending clinic visits preferred injections and implant over pills. Most participants indicated a willingness to use new LA ART formulations. However, 41% still prefers pills, and those more interested in LA-ART were not less adherent.

Entities:  

Keywords:  HIV; Long-acting antiretrovirals; acceptability; attitude; implants; survey

Year:  2020        PMID: 32408771     DOI: 10.1080/09540121.2020.1764906

Source DB:  PubMed          Journal:  AIDS Care        ISSN: 0954-0121


  9 in total

1.  Reasons People Living with HIV Might Prefer Oral Daily Antiretroviral Therapy, Long-Acting Formulations, or Future HIV Remission Options.

Authors:  Karine Dubé; Danielle M Campbell; Kelly E Perry; John T Kanazawa; Parya Saberi; John A Sauceda; Tonia Poteat; David Evans
Journal:  AIDS Res Hum Retroviruses       Date:  2020-09-14       Impact factor: 2.205

2.  Long-acting cabotegravir and rilpivirine for HIV-1 suppression: switch to 2-monthly dosing after 5 years of daily oral therapy.

Authors:  Anthony Mills; Gary J Richmond; Cheryl Newman; Olayemi Osiyemi; Jerry Cade; Cynthia Brinson; Jerome De Vente; David A Margolis; Kenneth C Sutton; Viviana Wilches; Sarah Hatch; Jeremy Roberts; Cynthia McCoig; Cindy Garris; Kati Vandermeulen; William R Spreen
Journal:  AIDS       Date:  2022-02-01       Impact factor: 4.177

3.  Are Patients and Their Providers Talking About Long-Acting Injectable Antiretroviral Therapy? Penetration into Clinical Encounters at Three U.S. Care Sites.

Authors:  Katerina A Christopoulos; Jonathan Colasanti; Mallory O Johnson; Manami Diaz Tsuzuki; Xavier A Erguera; Rey Flores; Jared Kerman; Kaylin Dance; John A Sauceda; Torsten B Neilands; Samantha E Dilworth; Kimberly A Koester; Jose Gutierrez; John A Schneider; Elizabeth Montgomery; Moira C McNulty
Journal:  Open Forum Infect Dis       Date:  2022-06-11       Impact factor: 4.423

4.  "A dream come true": Perspectives on long-acting injectable antiretroviral therapy among female sex workers living with HIV from the Dominican Republic and Tanzania.

Authors:  Deanna Kerrigan; Tahilin Sanchez Karver; Ohvia Muraleetharan; Virginia Savage; Jessie Mbwambo; Yeycy Donastorg; Samuel Likindikoki; Martha Perez; Hoisex Gomez; Andrea Mantsios; Miranda Murray; S Wilson Beckham; Wendy Davis; Noya Galai; Clare Barrington
Journal:  PLoS One       Date:  2020-06-12       Impact factor: 3.240

5.  Week 96 extension results of a Phase 3 study evaluating long-acting cabotegravir with rilpivirine for HIV-1 treatment.

Authors:  Susan Swindells; Thomas Lutz; Lelanie Van Zyl; Norma Porteiro; Matthias Stoll; Essack Mitha; Alyssa Shon; Paul Benn; Jenny O Huang; Conn M Harrington; Kai Hove; Susan L Ford; Christine L Talarico; Vasiliki Chounta; Herta Crauwels; Rodica Van Solingen-Ristea; Simon Vanveggel; David A Margolis; Kimberly Y Smith; Kati Vandermeulen; William R Spreen
Journal:  AIDS       Date:  2022-02-01       Impact factor: 4.632

6.  Patient-Reported Outcomes Through 1 Year of an HIV-1 Clinical Trial Evaluating Long-Acting Cabotegravir and Rilpivirine Administered Every 4 or 8 Weeks (ATLAS-2M).

Authors:  Vasiliki Chounta; Edgar T Overton; Anthony Mills; Susan Swindells; Paul D Benn; Simon Vanveggel; Rodica van Solingen-Ristea; Yuanyuan Wang; Krischan J Hudson; Mark S Shaefer; David A Margolis; Kimberly Y Smith; William R Spreen
Journal:  Patient       Date:  2021-05-31       Impact factor: 3.883

7.  Patient and Physician Preferences for Regimen Attributes for the Treatment of HIV in the United States and Canada.

Authors:  Heather Gelhorn; Cindy Garris; Erin Arthurs; Frank Spinelli; Katelyn Cutts; Gin Nie Chua; Hannah Collacott; Bertrand Lebouché; Erik Lowman; Howard Rice; Sebastian Heidenreich
Journal:  J Pers Med       Date:  2022-02-23

8.  Acceptability of Pre-Exposure Prophylaxis and Non-Occupational Post-Exposure Prophylaxis among Men Who Have Sex with Men in Guilin, China.

Authors:  Lingmi Zhou; Sawitri Assanangkornchai; Zhaohui Shi; Fusheng Jiang; Dong Yang; Wuxiang Shi
Journal:  Int J Environ Res Public Health       Date:  2022-03-17       Impact factor: 3.390

Review 9.  The LAIs Are Coming! Implementation Science Considerations for Long-Acting Injectable Antiretroviral Therapy in the United States: A Scoping Review.

Authors:  John T Kanazawa; Parya Saberi; John A Sauceda; Karine Dubé
Journal:  AIDS Res Hum Retroviruses       Date:  2020-12-07       Impact factor: 2.205

  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.